"We're proud to offer BEYFORTUS doses to help protect every eligible baby in the US this RSVseason. This accomplishment aimed at equitable access was made possible through close partnership ...
BEYFORTUS is the first and only long-acting monoclonal antibody approved for the prevention of RSV lower respiratory tract disease (LRTD) in newborns and infants born during or entering their ...
Company planning for every eligible baby in the US to have access to BEYFORTUS New BEYFORTUS filling line approved by the U.S. Food and Drug Administration (FDA) to expand manufacturing capacity ...
Some results have been hidden because they may be inaccessible to you